UnitedHealthcare Community Plan

Hyperlipidemia Agents - Texas
Prior Authorization Request Form

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826.**
This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.
Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance Information (if any):		

Is the requested medication: □ New or □ Continuation of Therapy? If continuation, list start date: _____

Is this patient currently hospitalized? □ Yes □ No If recently discharged, list discharge date: _____

Section B - Provider Information

First Name:		Last Name:		M.D./D.O.
Address:		City:	State:	ZIP code:
Phone:	Fax:	NPI #:	Specialty:	
Office Contact Name / Fax attention to:				

Section C - Medical Information

Medication:	**Strength:**
Directions for use:	**Quantity:**
Diagnosis (Please be specific & provide as much information as possible)**:**	**ICD-10 CODE:**

Is this member pregnant? □ Yes □ No If yes, what is this member's due date? _____

Section D – Previous Medication Trials

Medication Name	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs: Please refer to the patient's PDL at www.uhcprovider.com for a list of preferred alternatives

UnitedHealthcare Community Plan

Hyperlipidemia Agents - Texas
Prior Authorization Request Form

Member First name:	Member Last name:	Member DOB:

Clinical and Drug Specific Information

JUXTAPID	
□ **Yes** □ **No**	**Does the patient have a diagnosis of homozygous familial hypercholesterolemia (HoFH)?**
Document the patient's low-density lipoprotein cholesterol (LDL-C): _____ mg/dL	
□ **Yes** □ **No**	**Is the patient currently pregnant?**
□ **Yes** □ **No**	**Does the patient have a diagnosis of moderate or severe hepatic impairment?**
□ **Yes** □ **No**	**Has the patient had any of the following in the last 730 days?** *(If yes, check which applies and complete Section D above)* □ 90 consecutive days of high dose atorvastatin therapy □ 90 consecutive days of high dose rosuvastatin therapy □ 90 consecutive days of ezetimibe therapy
□ **Yes** □ **No**	**If applicable, has the patient shown clinical response (significant lowering of LDL-C) since initiation of Juxtapid therapy?** *If yes, document LDL-C and % lowered:*
PRALUENT	
□ **Yes** □ **No**	**Does the patient have one of the following diagnoses?** *(If yes, check which applies)* □ Clinical atherosclerotic cardiovascular disease (ASCVD) □ Primary hyperlipidemia
Document the patient's low-density lipoprotein cholesterol (LDL-C): _____ mg/dL	
□ **Yes** □ **No**	**Has the patient had any of the following in the last 730 days?** *(If yes, check which applies and complete Section D above)* □ 90 consecutive days of high dose atorvastatin therapy □ 90 consecutive days of high dose rosuvastatin therapy □ 90 consecutive days of ezetimibe therapy
□ **Yes** □ **No**	**If applicable, has the patient shown clinical response (significant lowering of LDL-C) since initiation of PCSK9 inhibitor therapy?** *If yes, document LDL-C and % lowered:*
REPATHA	
□ **Yes** □ **No**	**Does the patient have one of the following diagnoses?** *(If yes, check which applies)* □ Clinical atherosclerotic cardiovascular disease (ASCVD) □ Homozygous familial hypercholesterolemia □ Primary hyperlipidemia
Document the patient's low-density lipoprotein cholesterol (LDL-C): _____ mg/dL	
□ **Yes** □ **No**	**Has the patient had any of the following in the last 730 days?** *(If yes, check which applies and complete Section D above)* □ 90 consecutive days of high dose atorvastatin therapy □ 90 consecutive days of high dose rosuvastatin therapy □ 90 consecutive days of ezetimibe therapy
□ **Yes** □ **No**	**If applicable, has the patient shown clinical response (significant lowering of LDL-C) since initiation of PCSK9 inhibitor therapy?** *If yes, document LDL-C and % lowered:*

Provider Signature: _____ **Date:** _____